KYBORA helps Daewoong license the China rights of its early stage IPF compound to CS-Pharma for $336M, including $76M in upfront and development milestones payments.
The Challenge
In January 2022, Daewoong, a leading South Korean pharmaceutical company, reached out to KYBORA to assist them with licensing DWN12088, an early-stage Idiopathic Pulmonary Fibrosis (IP F) to CS Pharma. Specifically, Daewoong needed to ensure that the terms it was receiving from CS Pharma were appropriate.
The Solution
KYBORA performed a complete market assessment including primary and secondary research, evaluation of regulatory pathways in China, pricing and reimbursement, and time to market. All this information was then included in KYBORA’s proprietary deal valuation model which allowed Daewoong to make its decision.
The Outcome
Daewoong signed a lucrative licensing agreement that will help it bring a differentiated IPF product to patients in China. The model KYBORA built allowed them to sign a win-win agreement with CS Pharma.
To download the Daewoong success story, please click here.
